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E-mail: snakao@med3.m.kanazawa-u.ac.jpValproic acid (VPA), a histone deacetylase inhibitor, upregulates
NKG2D ligands (NKG2DLs) on some monocytic and lymphoid leu-
kemic cells. However, its effect on myeloid leukemia cells and syn-
ergistic agents that can augment the effect of VPA remains
unknown. Of the various myeloid cell lines examined, OUN-1, a
chronic myelogenous leukemia cell line, showed the most promi-
nent upregulation of MICA ⁄B and ULBP2 in response to VPA. The
NKG2DL upregulation was observed only in leukemic cells without
apoptosis and the effect was abrogated by pretreatment of cells
with caffeine, an inhibitor of ATM ⁄ATR. Several activators of
ATM ⁄ATR were screened for their effect on NKG2DL expression,
but only hydroxyurea (HU) efficiently upregulated both MICA ⁄B
and ULPB2 expression on the cell line. VPA and HU synergistically
upregulated the NKG2DLs on OUN-1 cells as well as primary leuke-
mic cells from some patients with acute myeloid leukemia. The
upregulation of NKG2DLs by VPA and ⁄or HU was associated with
increased transcription of each NKG2DL gene. OUN-1 cells treated
with VPA + HU were more susceptible to killing by natural killer
(NK) cells than untreated cells and the enhanced cytotoxicity of NK
cells was blocked by the treatment of NK cells with anti-NKG2D
monoclonal antibodies. The same concentrations of VPA and HU
did not affect the cytotoxicity of NK cells against OUN-1 cells.
These data suggest that VPA and HU might enhance the NK cell-
mediated antileukemia effect by increasing the susceptibility of
myeloid leukemic cells to NK cells. (Cancer Sci 2010; 101: 609–615)
N atural killer (NK) cells play an essential role in the eradi-cation of myeloid leukemia cells after allogeneic stem cell
transplantation.(1–3) Several lines of evidence indicate that the
expression level of NKG2D ligand (NKG2DL) on leukemia
cells affects the sensitivity of the leukemic cells to killing by
NK cells.(4–11) Various agents have been evaluated for their
inducibility of NKG2DLs on leukemic cells, to augment the NK
cell-mediated antileukemia effect.(4,8,9,12–14) Valproic acid
(VPA), a histone deacetylase inhibitor, is a potent inducer of
NKG2DLs such as MICA ⁄B and ULBPs on malignant
cells.(9,12,14) VPA augments the expression of MICA and
ULBP2 on several monocytic and lymphoid leukemia cell lines
and primary acute myeloid leukemia (AML) cells in vitro and
in vivo.(9,12) However, the mechanisms for the upregulation of
NKG2DL on AML cells by VPA has not been studied exten-
sively due to the lack of myeloid leukemia cell lines that display
an upregulation of NKG2DLs in response to VPA. Clarifying
the mechanisms associated with upregulation could identify
other reagents that synergize with VPA to augment the expres-
sion of NKG2DL by myeloid leukemia cells and thereby
enhance the susceptibility of leukemic cells to NK cells.doi: 10.1111/j.1349-7006.2009.01439.x
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ATR and ATM.(10,15,16) Several reagents, including hydroxyurea
(HU) and cisplastin, as well as physical stress, such as ionizing
irradiation, activate ATM ⁄ATR.(17,18) Some of the ATR activa-
tors might not only induce apoptosis of myeloid leukemia
cells(19) but might also synergize with VPA in the induction of
NKG2DL expression in leukemic cells, and thereby enhance the
sensitivity of the leukemic cells to NK cell-mediated cytotoxic-
ity if the agents do not impair the NK cell function.
This study screened various myeloid leukemia cell lines for
the upregulation of NKG2DL expression induced by VPA and
investigated mechanisms for the upregulation. This report
describes the synergistic effect of HU with VPA in the induction
of NKG2DL on myeloid leukemia cells that were not suscepti-
ble to apoptosis.
Materials and Methods
Leukemia cells. Myeloid cell lines derived from chronic mye-
loid leukemia, including KH88, SAS413, and OUN-1, and an
AML cell line, NB4, were kindly provided by Dr. Masaki
Yasukawa of Ehime University (Matsuyama, Japan). K562 was
purchased from the Health Science Research Resources Bank
(Osaka, Japan). A Burkitt’s lymphoma cell line Daudi, T-cell
leukemia cell lines Molt-4 and Jurkat, an AML cell line HL60, a
chronic myeloid leukemia cell line KU812, and monocytic
leukemia cell lines U937 and THP-1 were purchased from
RIKEN BRC (Ibaraki, Japan). These cell lines were maintained
in RPMI-1640 supplemented with 100 U ⁄mL penicillin,
100 lg ⁄mL streptomycin, and 10% FBS. Primary leukemic cells
were isolated using the density gradient method from either the
peripheral blood or bone marrow aspirates containing >90% leu-
kemic cells of five patients with AML aged between 25 and
52 years. The leukemic cells were cryopreserved until use. All
patients provided their informed consent for the use of their
samples and this study protocol was approved by the institu-
tional ethical committee.
Monoclonal antibodies and reagents. Valproic acid, HU, cis-
platin, CPT-11, and doxorubicin were purchased from Sigma
(Kyowa Hakko Kogyo, Tokyo, Japan). Caffeine, cyclosporine,
FK506, SB202190, BAPTA-AM, PD98059, and JNK-1were
purchased from Sigma. mAbs specific to MICA ⁄B, ULBP1,
ULBP2, ULBP3, and anti-NKG2D were purchased from R&D
Systems (Minneapolis, MN, USA). FITC-conjugated goat
antimouse IgG, annexin V–phycoerythrin (PE), anti-CD3-PE,Cancer Sci | March 2010 | vol. 101 | no. 3 | 609–615
anti-CD56-PE-Cy5, and anti-CD107a-FITC were all purchased
from BD PharMingen (San Diego, CA, USA).
Flow cytometry. The cells were stained with the appropriate
Abs or the respective isotype control Abs, followed by incubation
with FITC-conjugated goat antimouse IgG. An annexin V–PE
apoptosis detection kit I from BD PharMingen was used accord-
ing to the instructions of the manufacturer. Data acquisition and a
flow cytometric analysis were carried out on a BD FACSCalibur
using the CellQuest software package (BD Biosciences, Franklin
Lakes, NJ, USA).
RNA extraction and real-time PCR. RNA was isolated using
Isogen (Nippon Gene, Tokyo, Japan) according to the manufac-
turer’s instructions. The reverse transcription of 1 lg RNA into
cDNA was carried out using Superscript II reverse transcriptase
(Invitrogen, Carlsbad, CA, USA) and stored at )20C until use.
The quantification of NKG2DL gene expression was carried out
using a LightCycler (Roche Diagnostics, Tokyo, Japan) with
specific primers. The LightCycler with a GAPDH primer kit
(Search-LC, Heidelberg, Germany) was used for quantification
of mRNA for GAPDH, a housekeeping gene, in the same sam-
ples. The relative amount of NKG2DL mRNA to GAPDH
mRNA (NKG2DL ⁄GAPDH) was used to represent expression
levels of the NKG2D-L gene.(20) PCR was carried out using
standard conditions. The PCR used the sense primer 5¢-
GCCATGAACGTCAGGAATTT-3¢ and antisense primer 5¢-
GACGCCAGCTCAGTGTGATA-3¢ for MICA, and the sense
primer 5¢-TTACTTCTCAATGGGAGACTGT-3¢ and antisense
primer 5¢-TGTGCCTGAGGACATGGCGA-3¢ for ULBP2. The
housekeeping gene GAPDH was used as a loading control sense
primer 5¢-CTATTCGATGCCGTGTATGC-3¢, and antisense pri-
mer 5¢-GCCTGGTCCAGACTTCTTTC-3¢.
Natural killer cell preparation. Peripheral blood mononuclear
cells (PBMCs) were isolated from a healthy individual and two
patients with AML using density gradient centrifugation. Then
106 PBMCs were cultured with 2 · 105 irradiated (45 Gy) K562
cells transfected with the membrane-bound form of interleukin-15
and human 4-1BBL (K562-mb15-41BBL) in RPMI-1640 contain-
ing 10% FBS, 50 U ⁄mL penicillin, 50 lg ⁄mL streptomycin, and
100 IU ⁄mL interleukin-2 for 14 d.(21) The cultured PBMCs con-
tained >90% CD3)CD56+CD16+ NK cells. In some experiments,
the cultured NK cells were incubated in the presence of VPA or
VPA + HU, washed once with PBS, then used as effector cells.
Drug treatment of leukemic cells. Leukemic cell lines were
cultured for 24 h in 24-well tissue culture plates at 37C and 5%
CO2 in the absence or presence of different drug concentrations.
The following therapeutic drugs were tested: 200 lg ⁄mL VPA;
20 lg ⁄mL HU; 10 lM cisplatin; 100 lM CPT-11; and 0.05 lM
doxorubicin. Primary AML cells were cultured for 48 h in the
complete medium containing growth factors including Flt3
ligand at 100 ng ⁄mL, stem cell factor at 100 ng ⁄mL, and granu-
locyte macrophage colony stimulating factor at 20 ng ⁄mL (all
from Amgen, Thousand Oaks, CA, USA)(22) with or without
VPA and ⁄or HU. In some experiments, leukemic cells were
incubated for 1 h at 37C in the presence of 5 mM caffeine,
1 lM cyclosporine, 1 lM FK506, 10 lM SB202190, 5 lM
BAPTA-AM, 10 lM PD98059, or 5 lM JNK-1 prior to culture
with VPA.
Cytotoxicity assay. NK cell cytotoxicity against leukemic cell
lines was assessed using the standard chromium release assay,
as described previously.(23) In blocking experiments, anti-
NKG2D Abs were added to the NK cell suspension at
10 lg ⁄mL and incubated at 37C for 30 min before the addition
of target cells. The percentage of specific lysis was calculated
using the formula: 100 · (count per minute [cpm] released from
test sample ) cpm spontaneous release) ⁄ (cpm maximum
release ) cpm spontaneous release).
CD107a mobilization assay. Two microliters of FITC-
CD107a mAb was added to the suspension of effector and target610cell mixtures in 96-well round microplates and incubated for 3 h
at 37C. One microliter of 2 mM monencin (Sigma) in 100%
ethanol was included in the cell suspension to prevent the acidi-
fication of the endosomal compartment, which could alter the
fluorescence of internalized CD107a:FITC-CD107a mAb com-
plexes. After the incubation, the plate was centrifuged to the pel-
let cells and the supernatant was removed. Cell–cell conjugate
was disrupted by washing the cell with PBS supplemented with
0.02% azide and 0.5 mM EDTA. Samples were then mixed
vigorously then stained with mAbs specific for CD3 and CD56,
followed by flow cytometric analysis.(24)
Statistical method. Differences in the expression levels of
NKG2DL in leukemia cell lines were assessed using Student’s
t-test.
Results
Upregulation of NKG2DL on leukemic cell lines induced by
VPA. Several myeloid and lymphoid leukemic cells were exam-
ined for the expression of MICA ⁄B and ULBP1–3 before and
after incubation in the presence of VPA in order to identify a
cell line suitable for the screening of the agents that can aug-
ment VPA-induced NKG2DL expression. Three myeloid cell
lines, as well as Molt-4 and Jurkat, showed apparent upregula-
tion of both MICA ⁄B and ULBP2 after incubation with VPA
(Fig. 1a,b). Time-course experiments revealed 24 h of incuba-
tion in the presence of VPA to be optimal for the maximum
induction of MICA ⁄B and ULBP2 in OUN-1 cells. The upregu-
lation shown in the histogram was most evident in OUN-1 cells
(Fig. 1a), thus, this cell line was chosen for the further analyses.
Agents that upregulate NKG2DLs on leukemic cells induce
apoptosis(19,25–27) and examination of the total cell population
after VPA treatment might underestimate the inducibility of
NKG2DL by the agents due to the presence of apoptotic cells.
Indeed, when apoptotic and non-apoptotic cells were examined
separately after VPA treatment, the apparent upregulation of
MICA ⁄B and ULBP2 was only observed in annexin V-negative
non-apoptotic cells (Fig. 1c). The mean fluorescence intensity
levels of MICA ⁄B on VPA treated or untreated OUN-1 cells
were 10.4 ± 2.3 and 4.8 ± 1.5 (P < 0.05), respectively; the
mean fluorescence intensity levels of ULBP2 on VPA treated or
untreated OUN-1 cells were 12.9 ± 2.9 and 6.1 ± 1.7
(P < 0.05), respectively. Therefore, only the annexin V-negative
cell population was observed in the subsequent analyses.
Although little is known about the mechanisms for the upreg-
ulation of NKG2DL by VPA, the expression of NKG2DL is
controlled by ATM ⁄ATR kinase and various signaling pathways
affect the expression of NKG2DL by T cells.(16,28) Various
inhibitors were tested for their ability to block NKG2DL expres-
sion to determine which pathway mediates the upregulation
of NKG2DL in OUN-1 cells (Fig. 1d). Only caffeine, an
ATM ⁄ATR inhibitor, abrogated the upregulation of NKG2DL
induced by VPA, suggesting ATM ⁄ATR kinases are involved in
NKG2DL induction.
Effect of ATM ⁄ATR activators on OUN-1. Several reagents
capable of stimulating ATM ⁄ATR were examined for the induc-
ibility of MICA ⁄B and ULBP2 on OUN-1 cells. HU induced
expression of both MICA and ULBP2 on OUN-1 cells, whereas
cisplatin and CPT-11 failed to show such stimulatory effects
(Fig. 2a). Doxorubicin, an agent capable of upregulating
NKG2DLs on multiple myeloma cells,(10) upregulated MICA ⁄B
alone. In addition, the upregulation of the NKG2DL by HU was
only evident in non-apoptotic cells (Fig. 2b).
Synergism of HU and VPA in the upregulation of NKG2DL
expression. The treatment of OUN-1 cells with HU and VPA
upregulated NKG2DL expression to a greater degree than HU or
VPA alone (Fig. 3a,b). This synergistic effect was also observed
in leukemic cells from two of three patients with AML fromdoi: 10.1111/j.1349-7006.2009.01439.x





Fig. 1. Upregulation of NKG2D ligand (NKG2DL) expression on leukemic cell lines by treatment with valproic acid (VPA). (a) Histograms of
NKG2DL expression on three myeloid leukemia cell lines are shown. Green lines, untreated cells; purple lines, isotype control; red lines, VPA
treated cells. (b) Changes in the mean fluorescence intensity (MFI) level of MICA ⁄ B and ULBP2 in various leukemic cell lines. Each column
represents the difference in the MFI level calculated by subtracting the MFI level of untreated cells from that of VPA treated cells. The
differences in the MFI levels are indicated as the mean + SD from three independent experiments. *P < 0.05. (c) Selective upregulation of
NKG2DLs by VPA treatment on non-apoptotic OUN-1 cells. Apoptotic and non-apoptotic cells defined by the expression of annexin V were
separately assessed for the expression of NKG2DLs. Green lines, untreated cells; red lines, VPA treated cells. (d) Effect of various reagents on
VPA-induced MICA ⁄ B and ULBP2 expression by OUN-1 cells. OUN-1 cells were pretreated with the indicated reagent for 1 h and were incubated
in the presence of VPA. Each column represents the difference in the MFI level calculated by subtracting the MFI level of untreated cells from
that of VPA treated cells. BAPTA-AM, calcium chelator; CsA, cyclosporine; FK506, tacrolimus; JNK-1, an inhibitor of JNK; PD98059, an inhibitor of
ERK1 ⁄ 2; SB202190, an inhibitor of p38MAPK.
(a) (b)
Fig. 2. Effect of ATM ⁄ATR activators on the expression of NKG2D ligand (NKG2DL) by chronic myelogenous leukemia cell line OUN-1. (a) OUN-1
cells were incubated in the presence of 20 lg ⁄mL hydroxyurea (HU), 10 lM cisplatin, 100 lM CPT-11, or 0.05 lM doxorubicin for 24 h. Each
column represents the difference in the mean fluorescence intensity (MFI) level calculated by subtracting the MFI level of untreated cells from
that of the cells treated with the indicated reagent. (b) Selective upregulation of NKG2DLs by HU treatment on non-apoptotic OUN-1 cells.
Apoptotic and non-apoptotic cells defined by the expression of annexin V were separately assessed for the expression of NKG2DLs. Green lines,
untreated cells; red lines, HU treated cells.whom a sufficient number of leukemic cells could be obtained.
The synergistic effect on OUN-1 cells was abolished by pre-
treatment of the cells with caffeine (Fig. 3c). When the mRNA
levels of the NKG2DLs were compared between untreated andLu et al.treated cells using real-time PCR, both VPA and HU treated
cells showed 2.5-fold higher MICA ⁄B RNA and ULBP2 mRNA
levels than untreated cells. The combined use of VPA and HU
further increased the mRNA levels to 3.5-fold of the controlCancer Sci | March 2010 | vol. 101 | no. 3 | 611





Fig. 3. Synergistic effect of valproic acid (VPA) and hydroxyurea (HU) on NKG2D ligand (NKG2DL) expression by OUN-1 chronic myelogenous
leukemia cells. (a) OUN-1 cells and primary leukemic cells from five patients with acute myeloid leukemia were treated with VPA, HU, or
VPA + HU for either 24 h (OUN-1) or 48 h (primary leukemic cells). Each column represents the difference in the mean fluorescence intensity
(MFI) level calculated by subtracting the MFI level of untreated cells from that of the cells treated with the indicated condition. Leukemic cells
from Patients 3–5 were only examined for the inducibility of MICA ⁄ B and ULBP2 by VPA or HU alone. (b) Representative histograms of OUN-1
and Patient 1’s leukemic cells treated with VPA and HU. Green lines, untreated cells; green lines, cells treated with VPA + HU; purple lines,
isotype control; red lines, VPA treated cells. (c) Effect of caffeine on the expression of NKG2DLs induced by VPA + HU. OUN-1 cells were
pretreated with 5 mM caffeine then incubated with either HU or VPA + HU for 24 h. (d) Effect of VPA and HU on the expression of MICA ⁄ B and
ULBP2 genes. The gene expression levels relative to GAPDH were determined using real-time PCR. Each column and error bar represents the
mean ± SD of the ratios of the NKG2DL mRNA level to the GAPDH mRNA level from three independent experiments. *P < 0.01.(Fig. 3d). These findings indicate the transcriptional upregula-
tion of each gene to underlie the augmentation of the NKG2DL
expression induced by these reagents.
Effect of leukemic cell pretreatment with VPA and HU on NK
cell-mediated cytotoxicity. The cytotoxicity of NK cells isolated
from healthy individuals was examined against OUN-1 cells
treated with or without NKG2DL inducers. Treatment of
OUN-1 cells with VPA or VPA + HU significantly increased
the cytotoxicity, although the enhancing effect by VPA + HU
was comparable to that by VPA alone (Fig. 4A). The enhancing
effect of VPA was blocked by the pretreatment of OUN-1 cells
with anti-NKG2D mAbs (Fig. 4B). VPA treatment of leukemic
cells obtained from two AML patients also increased the612cytotoxicity by autologous NK cells and the enhancing effect of
VPA was blocked by the pretreatment of leukemic cells with
anti-NKG2D mAbs (Fig. 4C). A 51Cr-release assay and degran-
ulation assay indicated that the treatment of NK cells with VPA
or VPA + HU did not affect their cytotoxicity against OUN-1
cells (Fig. 4D,E), thus suggesting that NK cells can exert cyto-
toxicity against leukemic cells in the presence of these agents.
Discussion
NKG2DL expression on leukemic cells plays a key role in the
antileukemia effect by NK cells because NKG2D can mediates
cytotoxicity depending on the NKG2DL expression levels ondoi: 10.1111/j.1349-7006.2009.01439.x








Fig. 4. Enhanced natural killer (NK) cell-mediated lysis of OUN-1 chronic myelogenous leukemia cells following treatment with valproic acid
(VPA) and hydroxyurea (HU). (A) OUN-1 cells were incubated with or without 200 lg ⁄mL VPA or in combination with 20 lg ⁄mL HU for 24 h
then examined for their sensitivity to killing by cultured NK cells from a healthy individual. *P < 0.05. (B) OUN-1 cells treated with VPA + HU
were incubated in the presence or absence of anti-NKG2D mAb, then tested for their sensitivity to NK cell-mediated lysis. *P < 0.05; **P < 0.01.
(C) (a) Acute myeloid leukemia cells from two patients were incubated with or without 200 lg ⁄mL VPA for 48 h, and the cytotoxicity of cultured
NK cells from the patients against autologous leukemic cells was assessed by chromium release assay. (b) Cultured NK cells were incubated in the
presence of anti-NKG2D Abs or medium alone for 30 min then used for chromium release assay against VPA treated leukemic cells. (D) NK cells
were incubated in the presence or absence of VPA or VPA + HU for 24 h, and their cytotoxicity against VPA-treated OUN-1 cells was compared.
(E) Degranulation of NK cells that were treated with VPA or HU for 24 h in response to OUN-1 cells. The scattergrams represent the CD107a
expression by CD3)CD56+ NK cells after 3 h of incubation with OUN-1 cells. E:T, Effector: Target.leukemic cells, even in the presence of inhibitory signals
through a KIR-KIR-L interaction.(5) A previous AML patient
relapsed after allogeneic stem cell transplantation in association
with the loss of ULBP2 expression by AML cells.(21) If the
agents non-toxic to NK cells are capable of upregulating
NKG2DLs on leukemic cells, then those agents might potentiate
NK cell-mediated leukemic cell killing.Lu et al.Of the various agents that have been tested for their inducibil-
ity of NKG2DL expression, this study focused on the effect of
VPA because it has an antileukemia effect by itself, and its low
toxicity allows the use of other agents in combination.(9,19,29)
The screening of various myeloid leukemia cell lines identified
OUN-1 as a suitable cell line for the analysis of mechanisms
underlying the NKG2DL upregulation by VPA. The successfulCancer Sci | March 2010 | vol. 101 | no. 3 | 613
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blocking of the NKG2DL-inducing effect by caffeine led to
screening ATM ⁄ATR activators, and HU was found, for the first
time, to be a potent NKG2DL inducer on myeloid leukemia
cells. This antileukemic agent, with low toxicity, upregulated
NKGD2L expression on OUN-1 cells as well as on primary leu-
kemic cells from some patients with AML, synergistically with
VPA.
The effect of VPA on various cancer cells has been extensively
studied both in vitro and in vivo.(9,12,14,16) VPA increases the
transcription of MICA ⁄B without affecting ULBPs in hepatoma
cells.(14) Diermayr et al. showed the upregulation of ULBP1 and
MICA ⁄B on primary leukemic cells, thus resulting in their
increased sensitivity to NK cell-mediated killing.(5) A recent clin-
ical trial showed VPA increases the expression level of MICA,
ULBP2, and ULBP3 by AML cells in vivo.(9) However, despite
the large body of evidence for the upregulation of NKG2DLs on
leukemic cells, the mechanisms for NKG2DL induction
remained unknown, possibly due to the lack of suitable cell lines
for in vitro studies. The identification of OUN-1 as an NKG2DL
inducible myeloid leukemia cell line allowed the determination
that the ATR ⁄ATM pathway is involved in NKG2DL induction.
Genotoxic stress and stalled DNA replication induce NKG2DL
expression by activating a DNA damage checkpoint pathway
initiated by ATM or ATR protein kinase(15) and caffeine, an
inhibitor of ATM ⁄ATR catalytic activity, interferes with the
induction of MICA expression on activated T cells.(16) In addi-
tion to HU identified in the present study, the identification of
other ATM ⁄ATR activators could further help to upregulate
NKG2DL expression by myeloid leukemia cells.
The effects of various agents on the expression of NKG2DLS
have been assessed by analyzing the total cell populations
exposed to the agents with flow cytometry.(4,12,14,22) The present
study revealed that this method underestimates the upregulation
of NKG2DL expression by test agents because many of the614agents that upregulate NKG2DLs induce apoptosis of the target
cells and the apoptotic cells might fail to express NKG2DLs.
The understanding of this phenomenon should be particularly
important when primary leukemic cells are screened for their
response to NKG2DL inducers, because sensitive screening
methods are required to identify the optimal combination of
such inducers in AML cells of individual patients.
Hydroxyurea is often used to control the blood cell count in
patients with myeloproliferative disorders and AML as a pallia-
tive treatment.(30–32) A recent study showed that VPA and HU
can modulate the cell cycle and cooperatively induce apoptosis
of cancer cells.(19) Several clinical trials of VPA and all-trans
retinoic acid for patients with myeloid malignancies used HU to
control leukocytosis.(9,29) HU might synergize with VPA in
patients responsive to the combination therapy, not only by aug-
menting apoptosis of leukemic cells but also by increasing the
susceptibility of leukemic cells to NK cell-mediated cytotoxic-
ity. It is plausible that giving VPA and HU simultaneously
might further augment the NK cell-mediated killing of myeloid
leukemia cells by upregulating NKG2DLs. Clinical trials using
VPA in combination with HU are therefore warranted for the
palliative treatments of elderly patients with either AML or
myeloproliferative disorders.
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